&nbsp;

YVM-Poster-Letter-Size-Print-English.pdf

Nov 2023

Document

YVM-Poster-Letter-Size-Print-French.pdf

Nov 2023

Document

YVM-Poster-Tabloid-Size-Web-English.pdf

Nov 2023

Document

YVM-Poster-Letter-Size-Web-English.pdf

Nov 2023

Document

YVM-Poster-Letter-Size-Web-French.pdf

Nov 2023

Regimen

NIVL+RELA

Cancer Type:

Skin,

Melanoma

Intent: Palliative

Funding:

New Drug Funding Program

Nivolumab and Relatlimab - Advanced Melanoma (Unresectable or Metastatic Melanoma)

Drugs Used:

nivolumab / relatlimab

Quick Link(s):

Regimen Monograph

Nov 2024

Document

no-harm.png

Sep 2024

Drug

nivolumab / relatlimab

Other Name(s): Opdualag™

Quick Link(s):

Drug Monograph, Patient Info Sheet

Feb 2025

Regimen

NIVL+IPIL

Cancer Type:

Skin,

Melanoma

Intent: Neoadjuvant

Funding:

New Drug Funding Program

Nivolumab plus Ipilimumab - (Neo)adjuvant Resectable Macroscopic Stage III Melanoma

New Drug Funding Program

Nivolumab plus Ipilimumab - (Neo)adjuvant Resectable Macroscopic Stage III Melanoma

Drugs Used:

nivolumab,

ipilimumab

Quick Link(s):

Regimen Monograph

May 2025

Regimen

NIVL

Cancer Type:

Skin,

Melanoma

Intent: Adjuvant

Funding:

New Drug Funding Program

Nivolumab plus Ipilimumab - (Neo)adjuvant Resectable Macroscopic Stage III Melanoma

Drugs Used:

nivolumab

Quick Link(s):

Regimen Monograph

May 2025

Regimen

NIVL+IPIL

Cancer Type:

Gastrointestinal,

Hepatobiliary / Liver / Bile Duct

Intent: Palliative

Drugs Used:

nivolumab (Compassionate),

ipilimumab (Compassionate)

Quick Link(s):

Regimen Monograph

Sep 2025

Regimen

NIVL+IPIL

Cancer Type:

Gastrointestinal,

Colorectal

Intent: Palliative

Drugs Used:

nivolumab (Compassionate),

ipilimumab (Compassionate)